Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Ophthalmic Drug

PUBLISHER: SNS Research | PRODUCT CODE: 2070574

Cover Image

PUBLISHER: SNS Research | PRODUCT CODE: 2070574

The Retinal Disorder Drugs Market 2026 to 2036: Disease Landscape, Pipeline, Commercial Dynamics and Forecasts

PUBLISHED:
PAGES: 348 Pages; 105 Tables & Figures
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 3000
PDF & Excel (Site License)
USD 4500
PDF & Excel (Global License)
USD 7500

Add to Cart

Description

Table of Contents

List of Tables

Retinal disorders are a group of conditions affecting the light-sensitive tissue at the back of the eye, encompassing age-related macular degeneration, diabetic eye disease, inherited retinal diseases, retinal vein occlusion, and related inflammatory and degenerative conditions. Without timely treatment, many retinal disorders progress to irreversible central vision loss or blindness.

Drug therapy is the dominant treatment modality across retinal indications, with anti-VEGF biologics establishing intravitreal injection as the standard of care since 2006. Complement inhibitors, gene therapies, and sustained-release delivery platforms are now entering commercial adoption, broadening the therapeutic landscape beyond the anti-VEGF monoculture that has defined the market for two decades.

The global retinal disorder drugs market is forecast at $18.1 billion in 2026, expanding at a 6.4% CAGR through 2030, driven by aging demographics compounding AMD and geographic atrophy patient volumes, the global diabetes epidemic expanding the diabetic eye disease population, and new indication creation in previously untreatable conditions.

The anti-VEGF category is in structural transition as biosimilar entry reshapes pricing dynamics and accelerates physician adoption of premium differentiated formats including extended-dosing biologics and sustained-release implants. The approved landscape for geographic atrophy is supported by strengthening long-term clinical evidence, and a pipeline of next-generation complement mechanisms, systemic delivery approaches, and gene therapy-enabled sustained modulation is advancing toward Phase 3 readouts. Three Phase 3 wet AMD gene therapy programs are expected to report pivotal data in the near term, with outcomes that will define the retinal treatment landscape through 2036.

The competitive landscape has been repositioned by over $11 billion in announced deal value over the 2024 to 2026 period, as large-cap pharmaceutical companies strengthened their retinal gene therapy and novel mechanism positions through acquisition and licensing. Geographic growth is broadening across Asia Pacific, Middle East and Africa, and Latin and Central America markets alongside the established North American and European commercial base.

The “Retinal Disorder Drugs Market 2026 to 2036: Disease Landscape, Pipeline, Commercial Dynamics and Forecasts” report presents an in-depth assessment of the retinal disorder drugs market with forecasts from 2026 to 2036 and historical data from 2021, covering the disease biology and key application areas, approved therapies and biosimilar dynamics, R&D pipeline, future roadmap, competitive industry dynamics and M&A activity, delivery route innovation, value chain analysis, and strategic recommendations for market participants. The report additionally includes profiles and strategies of leading retinal drug developers.

Market size forecasts are segmented across 6 indications, 5 drug classes, 3 routes of administration, 3 distribution channels, 5 regional markets, and 26 country markets. The pipeline analysis covers 107 active clinical and late preclinical programs across five therapeutic areas and seven mechanistic classes.

Key Findings:

The report has the following key findings:

  • The global retinal disorder drugs market is forecast to reach $18.1 billion in 2026 and expand at a 6.4% CAGR through 2030, supported by aging populations, rising diabetes prevalence, and the emergence of new therapeutic categories for previously untreated indications.
  • The anti-VEGF category is undergoing a structural transition as multiple biosimilars to aflibercept and ranibizumab reshape pricing and market share, with biosimilar revenues projected to grow at a 25.9% CAGR through 2030.
  • Dry AMD and geographic atrophy have evolved from a zero-revenue indication into one of the fastest-growing segments, driven by the first approved complement inhibitors and a strong pipeline of next-generation therapies.
  • Wet AMD gene therapy is approaching a commercial inflection point comparable to the 2006 approval of ranibizumab. Multiple Phase 3 programs are advancing toward pivotal readouts that will help determine whether single-administration or infrequent-dosing gene therapies can displace chronic intravitreal injections as the standard of care through 2036.
  • The retinal disorder drugs pipeline represents the most mechanistically diverse development era in the market’s history. This report profiles 107 active clinical and late-preclinical programs spanning gene therapy, complement inhibition, vascular stabilization, oral and topical delivery platforms, and neuroprotection.
  • The competitive landscape has been repositioned by over $11 billion in announced deal value, as large pharmaceutical companies strengthened their retinal positions through acquisitions and licensing.
  • Regulatory engagement has become a core competitive variable in retinal drug development. A growing number of programs hold FDA RMAT designation, multiple wet AMD and XLRP programs hold concurrent RMAT and EMA PRIME designation, and the EU Joint Clinical Assessment introduces reimbursement risk across multiple major European markets simultaneously.
  • Emerging markets in Asia Pacific, Middle East & Africa, and Latin & Central America are projected to grow above the global average, supported by expanding specialist infrastructure, improving reimbursement, and biosimilar-driven accessibility.
  • Multiple gene therapies for inherited retinal diseases are projected to gain approval across several genotypes during the forecast period. Commercial success will depend on building critical infrastructure, including genetic testing networks, authorized treatment center capacity, and payer frameworks, well ahead of launch. The infrastructure gaps that slowed Luxturna’s commercial ramp after its 2017 approval remain the key benchmark.

Topics Covered:

The report covers the following topics:

  • Global retinal disorder drugs market sizing, segmentation, and forecasts from 2021 to 2036
  • Market drivers, barriers, and macro-environmental trends
  • Approved drug classes and leading commercial products across all major retinal disorders
  • Biosimilar competition and patent landscape across anti-VEGF and novel mechanism agents
  • Regulatory frameworks across the US, EU, Japan, and China
  • Development pipeline review across 107 active candidates
  • Advanced drug delivery technologies and innovation platforms
  • Future roadmap for retinal drug development to 2036
  • Retinal drugs value chain analysis
  • Company profiles and strategies of 74 leading ecosystem players
  • Competitive landscape including acquisitions, alliances, and consolidation
  • Strategic recommendations for developers, investors, and healthcare stakeholders

Key Questions Answered:

The report provides answers to the following key questions:

  • How large is the global retinal disorder drugs market in 2026 and how will it evolve through 2036?
  • What structural forces are driving market growth and what barriers constrain it?
  • How is biosimilar competition reshaping anti-VEGF pricing, formulary dynamics, and originator market share?
  • What are the regulatory approval pathways, expedited designation programs, and reimbursement frameworks that will determine commercial access timelines across the US, EU, Japan, and China?
  • Which indications, drug classes, delivery routes, and distribution channels will generate the highest growth through 2036?
  • Which country and regional markets offer the highest growth potential and what is driving geographic rebalancing?
  • What is the current status and commercial prospects of complement inhibition for geographic atrophy, and how will the next generation of complement mechanisms expand the market?
  • How is the inherited retinal disease gene therapy pipeline maturing across multiple genotypes and what commercial barriers must be addressed before approval translates to revenue scale?
  • What novel delivery routes including sustained-release implants, suprachoroidal, subretinal, topical, and oral platforms are advancing toward approval and how will they alter the competitive dynamic?
  • How has the recent M&A and licensing cycle repositioned the competitive landscape and which independent assets represent the next wave of partnership opportunity?
  • Who are the leading market participants, what strategies are they pursuing, and how are large-cap pharmaceutical companies repositioning across gene therapy and novel mechanism platforms?
  • How will wet AMD gene therapy Phase 3 readouts reshape the treatment landscape and what are the commercial infrastructure requirements for market entry?
  • What strategies should drug developers, investors, and healthcare stakeholders adopt to capitalize on market opportunities through 2036?

​Forecast Segmentation:

The report provides detailed revenue forecasts across multiple dimensions of the Retinal Disorder Drugs market, including:

Indications

  • AMD (Age-Related Macular Degeneration)
    • Wet AMD
    • Dry AMD
  • Diabetic Eye Disease
  • Retinal Vein Occlusion
  • Inherited Retinal Diseases
  • Other Retinal Disorders

Drug Class

  • Anti-VEGF Agents
    • Originator Anti-VEGF
    • Anti-VEGF Biosimilars
  • Corticosteroids
  • Gene and Cell Therapies
  • Complement Inhibitors
  • Other Therapies​

Route of Administration

  • Intravitreal
    • Standard Injections
    • Sustained-Release Implants
  • Oral, Systemic and Other
  • Subretinal

Distribution Channel

  • Hospital
  • Specialty Clinic
  • Retail Pharmacy

Regional Markets

  • Asia Pacific
  • Europe
  • Middle East & Africa
  • North America
  • Latin & Central America​

Country Markets

  • Australia
  • Brazil
  • Canada
  • China
  • Egypt
  • France
  • Germany
  • Greece
  • India
  • Israel
  • Italy
  • Japan
  • Mexico​
  • Netherlands
  • Poland
  • Portugal
  • Russia
  • Saudi Arabia
  • South Africa
  • South Korea
  • Spain
  • Switzerland
  • Taiwan
  • Turkey
  • UK
  • USA
  • Rest of World
Show more

Table of Contents

Chapter 1: Introduction

  • 1.1 Executive Summary
  • 1.2 Topics Covered
  • 1.3 Forecast Segmentation
  • 1.4 Key Questions Answered
  • 1.5 Key Findings
  • 1.6 Methodology
  • 1.7 Target Audience
  • 1.8 Companies & Organizations Mentioned
    • 1.8.1 Companies
    • 1.8.1 Regulatory Bodies & Organizations

Chapter 2: An Overview of Retinal Disorder Drugs

  • 2.1 What Are Retinal Disorders?
  • 2.2 Anatomy of the Retina
    • 2.2.1 Layers of the Retina
      • 2.2.1.1 RPE (Retinal Pigment Epithelium)
      • 2.2.1.2 Photoreceptors Layer: Rod and Cone Cells
      • 2.2.1.3 External Limiting Membrane
      • 2.2.1.4 Outer Nuclear Layer
      • 2.2.1.5 Outer Plexiform Layer
      • 2.2.1.6 Inner Nuclear Layer
      • 2.2.1.7 Inner Plexiform Layer
      • 2.2.1.8 Ganglion Cell Layer
      • 2.2.1.9 Nerve Fiber Layer
      • 2.2.1.10 Internal Limiting Membrane
    • 2.2.2 Key Structural Elements
      • 2.2.2.1 Macula
      • 2.2.2.2 Fovea & Foveola
      • 2.2.2.3 Optic Disk & Optic Nerve
      • 2.2.2.4 Choroid
      • 2.2.2.5 Bruch’s Membrane
  • 2.3 Common Retinal Disorders
    • 2.3.1 AMD (Age-Related Macular Degeneration)
      • 2.3.1.1 Dry AMD
      • 2.3.1.2 Wet AMD
      • 2.3.1.3 Other Forms of Macular Degeneration
      • 2.3.1.4 Best’s Disease (Vitelliform Macular Dystrophy)
      • 2.3.1.5 Sorsby's Dystrophy
      • 2.3.1.6 Stargardt's Disease
    • 2.3.2 Diabetic Eye Disease
      • 2.3.2.1 Diabetic Retinopathy
      • 2.3.2.2 DME (Diabetic Macular Edema) & Maculopathy
    • 2.3.3 Hypertensive Retinopathy
    • 2.3.4 Macular Hole
    • 2.3.5 Macular Pucker
    • 2.3.6 Retinal Vascular Occlusion
      • 2.3.6.1 Retinal Artery Occlusion
      • 2.3.6.2 Retinal Vein Occlusion
    • 2.3.7 Retinal Tears
    • 2.3.8 Retinal Detachment
    • 2.3.9 Retinoblastoma
    • 2.3.10 Other Conditions
  • 2.4 The Role of Drugs in Retinal Disorder Treatment
    • 2.4.1 Anti-VEGF Therapy
    • 2.4.2 Corticosteroids
    • 2.4.3 Complement Inhibition and Dry AMD
    • 2.4.4 Gene Therapy and Emerging Modalities
    • 2.4.5 Other Drug-Based Treatments
  • 2.5 Other Treatment Options
    • 2.5.1 Laser Treatment
    • 2.5.2 Surgery
    • 2.5.3 Cryotherapy
    • 2.5.4 PDT (Photodynamic Therapy)
  • 2.6 Market Growth Drivers
    • 2.6.1 Impact of Retinal Disorders on Daily Life
    • 2.6.2 Growing Prevalence of Retinal Disorders
    • 2.6.3 Rising Incidence of Diabetes
    • 2.6.4 Longevity on the Rise
    • 2.6.5 Advances in Drug Delivery Technologies
    • 2.6.6 Detrimental Impact of Lifestyle Habits
  • 2.7 Market Barriers
    • 2.7.1 Lack of Awareness
    • 2.7.2 Patient Compliance
    • 2.7.3 Alternative Healing Options
    • 2.7.4 Innovator vs. Generic Disputes
    • 2.7.5 Lack of Healthcare Insurance

Chapter 3: Key Application Areas & Leading Therapies

  • 3.1 Key Application Areas
    • 3.1.1 Wet AMD (Neovascular Age-Related Macular Degeneration)
    • 3.1.2 Dry AMD & Geographic Atrophy
    • 3.1.3 Diabetic Eye Disease
    • 3.1.4 Retinal Vein Occlusion
    • 3.1.5 Inherited Retinal Disorders
    • 3.1.6 Other Retinal Disorders
  • 3.2 Leading Retinal Disorder Drugs
    • 3.2.1 Anti-VEGF Biologics
      • 3.2.1.1 Aflibercept
      • 3.2.1.2 Bevacizumab
      • 3.2.1.3 Brolucizumab
      • 3.2.1.4 Conbercept
      • 3.2.1.5 Faricimab
      • 3.2.1.6 Pegaptanib Sodium
      • 3.2.1.7 Ranibizumab
    • 3.2.2 Complement Inhibitors
      • 3.2.2.1 Avacincaptad Pegol
      • 3.2.2.2 Pegcetacoplan
    • 3.2.3 Corticosteroids
      • 3.2.3.1 Dexamethasone
      • 3.2.3.2 Fluocinolone acetonide
      • 3.2.3.3 Triamcinolone acetonide
    • 3.2.4 Cell and Gene Therapies
      • 3.2.4.1 Lenadogene nolparvovec
      • 3.2.4.2 Revakinagene taroretcel
      • 3.2.4.3 Voretigene neparvovec
    • 3.2.5 Other Approved Therapies
      • 3.2.5.1 Idebenone
      • 3.2.5.2 Ocriplasmin
      • 3.2.5.3 Valganciclovir
      • 3.2.5.4 Verteporfin
      • 3.2.5.5 Vincristine Sulfate
    • 3.2.6 Additional Therapies
  • 3.3 Opportunities for Generic & Biosimilar Drugs
    • 3.3.1 Patent Status and Biosimilar Landscape for Key Innovator Retinal Disorder Drugs
    • 3.3.2 The Ranibizumab Biosimilar Market
    • 3.3.3 The Aflibercept Biosimilar Transition
    • 3.3.4 Complement Inhibitor and Gene and Cell Therapy Exclusivity
    • 3.3.5 Emerging Market Biosimilar Dynamics

Chapter 4: R&D Pipeline and Prospects of New Therapies

  • 4.1 Key Areas of New Drug Development
    • 4.1.1 The Injection Burden Reduction Imperative
    • 4.1.2 Gene Therapy Reaching Pivotal Scale
    • 4.1.3 The Complement-Neuroprotection Frontier in Dry AMD
    • 4.1.4 The Oral and Topical Delivery Shift in Diabetic Eye Disease
    • 4.1.5 The Maturation of Inherited Retinal Disease Therapeutics
  • 4.2 Review of Pipeline Candidates Development
    • 4.2.1 Wet AMD
      • 4.2.1.1 Anti-VEGF & Angiogenesis Modulation
      • 4.2.1.2 Cell & Gene Therapy
      • 4.2.1.3 Biosimilars
      • 4.2.1.4 Others
    • 4.2.2 Dry AMD & Geographic Atrophy
      • 4.2.2.1 Complement & Cytokine Inhibitors
      • 4.2.2.2 Cell & Gene Therapy
      • 4.2.2.3 Anti-Inflammatory & Immunomodulatory
      • 4.2.2.4 Neuroprotective Agents
      • 4.2.2.5 Others
    • 4.2.3 Diabetic Eye Disease
      • 4.2.3.1 Anti-Inflammatory & Immunomodulatory
      • 4.2.3.2 Anti-VEGF & Angiogenesis Modulation
      • 4.2.3.3 Others
    • 4.2.4 Inherited Retinal Diseases (IRD)
      • 4.2.4.1 Stargardt Disease
      • 4.2.4.2 Retinitis Pigmentosa & Usher Syndrome
      • 4.2.4.3 Leber Hereditary Optic Neuropathy (LHON)
      • 4.2.4.4 Leber Congenital Amaurosis (LCA)
      • 4.2.4.5 Others
    • 4.2.5 Other Retinal Disorders
    • 4.2.6 Notable Discontinued and Stalled Programs
      • 4.2.6.1 Anti-VEGF Combination Failures in Wet AMD
      • 4.2.6.2 Complement Inhibitor Attrition in Geographic Atrophy
      • 4.2.6.3 XLRP Gene Therapy Failures
      • 4.2.6.4 Diabetic Eye Disease Anti-Inflammatory Failures
      • 4.2.6.5 Platform and Company Attrition

Chapter 5: Retinal Disorder Drugs Future Roadmap & Value Chain

  • 5.1 Future Roadmap
    • 5.1.1 Pre-2030: The Transition from Chronic Anti-VEGF Injection to Durable, Next-Generation Therapies
    • 5.1.2 2030 – 2033: Gene Therapy Commercialization and the Emergence of Functional Dry AMD Treatments
    • 5.1.3 2033 – 2036 & Beyond: Consolidation of a Durable, Precision-Driven Treatment Era
  • 5.2 Value Chain
    • 5.2.1 API Manufacturers & Enabling Technology Providers
    • 5.2.2 Generic and Biosimilar Drug Manufacturers
    • 5.2.3 Innovator Pharmaceutical Companies
    • 5.2.4 Regional Distributors
    • 5.2.5 Healthcare Providers, Pharmacies & Drug Stores

Chapter 6: Retinal Disorder Drugs Regulatory Landscape

  • 6.1 United States: FDA Regulatory Pathways
    • 6.1.1 Primary Approval Pathways
    • 6.1.2 Expedited Development Programs
    • 6.1.3 Reimbursement: Centers for Medicare and Medicaid Services
  • 6.2 European Union: EMA Regulatory Pathways
    • 6.2.1 HTA and Reimbursement: European Frameworks
  • 6.3 Japan: PMDA and Sakigake Designation
  • 6.4 China: NMPA Regulatory Pathways
  • 6.5 Biosimilar Regulatory Frameworks
    • 6.5.1 US FDA Biosimilar Framework
    • 6.5.2 European EMA Biosimilar Framework
    • 6.5.3 China NMPA Biosimilar Framework
    • 6.5.4 Japan PMDA Biosimilar Framework
    • 6.5.5 Rest of the World Biosimilar Frameworks
  • 6.6 Regulatory Designation Summary: Selected Retinal Pipeline Programs
  • 6.7 Regulatory Landscape: Commercial Implications

Chapter 7: Key Market Players

  • 7.1 4D Molecular Therapeutics
  • 7.2 AbbVie Inc.
  • 7.3 Adverum Biotechnologies (Eli Lilly and Company)
  • 7.4 Aldeyra Therapeutics
  • 7.5 Allegro Ophthalmics LLC
  • 7.6 Alteogen Inc.
  • 7.7 Amgen
  • 7.8 Amorphex Therapeutics
  • 7.9 Annexon Biosciences
  • 7.10 Astellas Pharma
  • 7.11 Bausch + Lomb
  • 7.12 Bayer
  • 7.13 Benitec Biopharma Inc.
  • 7.14 BioDiem
  • 7.15 Biogen
  • 7.16 Bioeq IP
  • 7.17 Lineage Cell Therapeutics Inc.
  • 7.18 BMS (Bristol-Myers Squibb)
  • 7.19 Cell Cure Neurosciences Ltd.
  • 7.20 Dompe Farmaceutici S.p.A.
  • 7.21 D.Western Therapeutics Institute Inc.
  • 7.22 Chengdu Kanghong Pharmaceuticals Group
  • 7.23 Optus Pharmaceuticals Co., Ltd.
  • 7.24 Kiora Pharmaceuticals Inc.
  • 7.25 PulseSight Therapeutics SAS
  • 7.26 FUJIFILM Cellular Dynamics, Inc. (FCDI)
  • 7.27 Fera Pharmaceuticals LLC
  • 7.28 Fidia Farmaceutici S.p.A.
  • 7.29 Formycon AG
  • 7.30 Gene Signal International SA
  • 7.31 Gensight Biologics S.A.
  • 7.32 Glaukos Corporation
  • 7.33 Glycadia Pharmaceuticals
  • 7.34 Healios
  • 7.35 Helvetic BioPharma
  • 7.36 HitGen Inc.
  • 7.37 ID Pharma Co., Ltd.
  • 7.38 InMed Pharmaceuticals Inc.
  • 7.39 Intas Pharmaceuticals Ltd.
  • 7.40 Isarna Therapeutics
  • 7.41 Johnson & Johnson Vision
  • 7.42 KalVista Pharmaceuticals
  • 7.43 Kissei Pharmaceutical
  • 7.44 Kodiak Sciences
  • 7.45 Kubota Vision Inc.
  • 7.46 Laboratorios SALVAT, S.A.
  • 7.47 Laboratorios Sophia, S.A.
  • 7.48 Lee’s Pharmaceutical Holdings
  • 7.49 MacuCLEAR Inc.
  • 7.50 Mimetogen Pharmaceuticals Inc.
  • 7.51 NeuMedics Inc.
  • 7.52 Neurotech Pharmaceuticals Inc.
  • 7.53 Novaliq GmbH
  • 7.54 Novartis
  • 7.55 NovelMed Therapeutics Inc.
  • 7.56 Ocular Therapeutix Inc.
  • 7.57 InflammX Therapeutics
  • 7.58 ONL Therapeutics Inc.
  • 7.59 Oxford BioMedica
  • 7.60 Pfizer Inc.
  • 7.61 Sylentis (PharmaMar)
  • 7.62 Regeneron Pharmaceuticals Inc.
  • 7.63 REGENXBIO Inc.
  • 7.64 Roche Holding (F. Hoffmann-La Roche)
  • 7.65 Sanofi
  • 7.66 Santen Pharmaceutical Company
  • 7.67 Senju Pharmaceutical Company
  • 7.68 Spark Therapeutics Inc. (part of Roche Group)
  • 7.69 STADA Arzneimittel AG
  • 7.70 Stealth BioTherapeutics
  • 7.71 Stemedica Cell Technologies
  • 7.72 Sumitomo Pharma
  • 7.73 Vision Medicines
  • 7.74 Xbrane Biopharma

Chapter 8: Market Sizing & Forecasts

  • 8.1 Global Outlook for Retinal Disorder Drugs
  • 8.2 Revenue by Indication
    • 8.2.1 AMD
      • 8.2.1.1 Wet AMD
      • 8.2.1.2 Dry AMD
    • 8.2.2 Diabetic Eye Disease
    • 8.2.3 Retinal Vein Occlusion
    • 8.2.4 Inherited Retinal Diseases
    • 8.2.5 Other Retinal Disorders
  • 8.3 Revenue by Drug Class
    • 8.3.1 Anti-VEGF Agents
      • 8.3.1.1 Originator Anti-VEGF Drugs
      • 8.3.1.2 Anti-VEGF Biosimilars
    • 8.3.2 Corticosteroids
    • 8.3.3 Gene & Cell Therapies
    • 8.3.4 Complement Inhibitors
    • 8.3.5 Other Therapies
  • 8.4 Revenue by Route of Administration
    • 8.4.1 Intravitreal
      • 8.4.1.1 Standard Injections
      • 8.4.1.2 Sustained-Release Implants
    • 8.4.2 Oral / Systemic / Other
    • 8.4.3 Subretinal
  • 8.5 Revenue by Distribution Channel
    • 8.5.1 Hospital Distribution
    • 8.5.2 Retail Pharmacy
    • 8.5.3 Specialty Clinic
  • 8.6 Revenue by Region
    • 8.6.1 Asia Pacific
    • 8.6.2 Europe
    • 8.6.3 Middle East & Africa
    • 8.6.4 Latin & Central America
    • 8.6.5 North America
  • 8.7 Top Country Markets
    • 8.7.1 Australia
    • 8.7.2 Brazil
    • 8.7.3 Canada
    • 8.7.4 China
    • 8.7.5 Egypt
    • 8.7.6 France
    • 8.7.7 Germany
    • 8.7.8 Greece
    • 8.7.9 India
    • 8.7.10 Israel
    • 8.7.11 Italy
    • 8.7.12 Japan
    • 8.7.13 Mexico
    • 8.7.14 Netherlands
    • 8.7.15 Poland
    • 8.7.16 Portugal
    • 8.7.17 Russia
    • 8.7.18 Saudi Arabia
    • 8.7.19 South Africa
    • 8.7.20 South Korea
    • 8.7.21 Spain
    • 8.7.22 Switzerland
    • 8.7.23 Taiwan
    • 8.7.24 Turkey
    • 8.7.25 UK
    • 8.7.26 USA
    • 8.7.27 Rest of World (RoW)

Chapter 9: Conclusion & Strategic Recommendations

  • 9.1 Why is the Market Poised to Grow?
  • 9.2 Competitive Industry Landscape: Acquisitions, Alliances & Consolidation
    • 9.2.1 Biogen and Apellis Pharmaceuticals
    • 9.2.2 Eli Lilly
    • 9.2.3 AbbVie & REGENXBIO
    • 9.2.4 Roche & Poseida Therapeutics
    • 9.2.5 Sanofi
    • 9.2.6 Merck & EyeBio
    • 9.2.7 4D Molecular Therapeutics and Otsuka
    • 9.2.8 Nippon Shinyaku and Atsena Therapeutics
    • 9.2.9 From Specialist Dominated to Large Cap Contested
  • 9.3 Assessment of the Approved Anti-VEGF Landscape
  • 9.4 Complement Inhibition for Geographic Atrophy: Opportunity and Constraint
    • 9.4.1 The SYFOVRE Long-Term Evidence Shift
    • 9.4.2 Izervay Label Update and Commercial Position
    • 9.4.3 Commercial Adoption Pattern
    • 9.4.4 The Competitive Complement Landscape
    • 9.4.5 Commercial Trajectory Assessment
  • 9.5 R&D Pipeline Review: Prospects of New Therapies
    • 9.5.1 Long-Acting VEGF Inhibition and Sustained Delivery
    • 9.5.2 Gene & Cell Therapies
    • 9.5.3 Vascular Stabilization and Inflammatory Pathways
    • 9.5.4 Complement Inhibition
    • 9.5.5 Other Emerging Areas
  • 9.6 Towards New Delivery Routes
    • 9.6.1 Intravitreal Implants
    • 9.6.2 Suprachoroidal Drug Delivery
    • 9.6.3 Subretinal Delivery
    • 9.6.4 Topical Delivery to the Posterior Segment
    • 9.6.5 Oral and Systemic Delivery
    • 9.6.6 Nanotechnology and Novel Formulation Platforms
    • 9.6.7 Ciliary Muscle Electrotransfection
  • 9.7 Geographic Outlook: Which Markets Offer the Highest Growth Potential?
  • 9.8 Which Indications Will Drive Retinal Market Growth?
  • 9.9 Strategic Recommendations
Show more

List of Figures

​
  • Figure 1: Layers of the Retina
  • Figure 2: Anatomy of the Eye
  • Figure 3: Progression from Dry AMD to Wet AMD
  • Figure 4: Patent Status and Biosimilar Landscape for Key Innovator Retinal Disorder Drugs
  • Figure 5: Distribution of Retinal Disorder Drugs R&D Pipeline Candidates by Indication (%)
  • Figure 6: Retinal Disorders Drug Pipeline: Active Candidates by Therapeutic Area and Mechanistic Class
  • Figure 7: Dry AMD & Geographic Atrophy Pipeline Distribution by Mechanistic Class (%)
  • Figure 8: Diabetic Eye Disease Pipeline Candidates by Route (%): 42% use non-injection oral or topical delivery
  • Figure 9: Inherited Retinal Disease Pipeline Distribution by Indication (%)
  • Figure 10: Wet AMD Pipeline: Anti-VEGF & Angiogenesis Modulation Candidates
  • Figure 11: Wet AMD Pipeline: Cell & Gene Therapy Candidates
  • Figure 12: Wet AMD Pipeline: Biosimilar Candidates
  • Figure 13: Wet AMD Pipeline: Other Candidates
  • Figure 14: Dry AMD & Geographic Atrophy Pipeline: Complement & Cytokine Inhibitor Candidates
  • Figure 15: Dry AMD & Geographic Atrophy Pipeline: Cell & Gene Therapy Candidates
  • Figure 16: Dry AMD & Geographic Atrophy Pipeline: Anti-Inflammatory & Immunomodulatory Candidates
  • Figure 17: Dry AMD & Geographic Atrophy Pipeline: Neuroprotective Agent Candidates
  • Figure 18: Dry AMD & Geographic Atrophy Pipeline: Other Candidates
  • Figure 19: Diabetic Eye Disease Pipeline: Anti-Inflammatory & Immunomodulatory Candidates
  • Figure 20: Diabetic Eye Disease Pipeline: Anti-VEGF & Angiogenesis Modulation Candidates
  • Figure 21: Diabetic Eye Disease Pipeline: Other Candidates
  • Figure 22: Inherited Retinal Diseases (IRD) Pipeline: Stargardt Disease Candidates
  • Figure 23: Inherited Retinal Diseases (IRD) Pipeline: Retinitis Pigmentosa & Usher Syndrome
  • Figure 24: Inherited Retinal Diseases (IRD) Pipeline: LHON Candidates
  • Figure 25: Inherited Retinal Diseases (IRD) Pipeline: Leber Congenital Amaurosis (LCA) Candidates
  • Figure 26: Inherited Retinal Diseases (IRD) Pipeline: Other IRD Candidates
  • Figure 27: Other Retinal Disorders Drug Developmental Pipeline Candidates
  • Figure 28: Retinal Disorder Drugs Future Roadmap: 2026 - 2036
  • Figure 29: Retinal Disorder Drugs Value Chain
  • Figure 30: FDA Expedited Development Programs Relevant to Retinal Drugs
  • Figure 31: European HTA Frameworks and Reimbursement Considerations for Retinal Disorder Drugs
  • Figure 32: Regulatory Designation Profiles of Selected Retinal Pipeline Programs
  • Figure 33: Global Retinal Disorder Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 34: Global Retinal Disorder Drugs Revenue Table ($ Million) and YoY Growth: 2026 - 2036
  • Figure 35: Global Retinal Disorder Drugs Revenue by Indication ($ Billion): 2026 - 2036
  • Figure 36: Retinal Disorder Drugs Market Share % by Indication 2026 & 2036
  • Figure 37: Retinal Disorder Drugs Revenue by Indication ($ Million): 2026 - 2036
  • Figure 38: Global AMD Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 39: Global Wet AMD Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 40: Global Dry AMD Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 41: Global Diabetic Eye Disease Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 42: Global Retinal Vein Occlusion Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 43: Global Inherited Retinal Disease Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 44: Global Other Retinal Disorder Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 45: Retinal Disorder Drugs Revenue by Drug Class ($ Billion): 2026 - 2036
  • Figure 46: Retinal Disorder Drugs Revenue by Drug Class ($ Million): 2026 - 2036
  • Figure 47: Retinal Anti-VEGF Agents Revenue ($ Billion): 2026 - 2036
  • Figure 48: Retinal Originator Anti-VEGF Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 49: Retinal Anti-VEGF Biosimilar Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 50: Retinal Corticosteroid Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 51: Retinal Gene & Cell Therapies Revenue ($ Billion): 2026 - 2036
  • Figure 52: Retinal Complement Inhibitor Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 53: Retinal Other Therapies Revenue ($ Billion): 2026 - 2036
  • Figure 54: Retinal Disorder Drugs Revenue by Route of Administration ($ Billion): 2026 - 2036
  • Figure 55: Retinal Disorder Drugs Revenue by Route of Administration ($ Million): 2026 - 2036
  • Figure 56: Retinal Intravitreal Injections Revenue ($ Billion): 2026 - 2036
  • Figure 57: Retinal Standard Injections Revenue ($ Billion): 2026 - 2036
  • Figure 58: Retinal Sustained-Release Implants Revenue ($ Billion): 2026 - 2036
  • Figure 59: Retinal Oral / Systemic / Other Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 60: Retinal Subretinal Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 61: Global Retinal Disorder Drugs Revenue by Distribution Channel ($ Billion): 2026 - 2036
  • Figure 62: Global Retinal Disorder Drugs Revenue by Distribution Channel ($ Million): 2026 - 2036
  • Figure 63: Retinal Hospital Distribution Revenue ($ Billion): 2026 - 2036
  • Figure 64: Retinal Retail Pharmacy Revenue ($ Billion): 2026 - 2036
  • Figure 65: Retinal Specialty Clinic Revenue ($ Billion): 2026 - 2036
  • Figure 66: Global Retinal Disorder Drugs Revenue by Region ($ Billion): 2026 - 2036
  • Figure 67: Global Retinal Disorder Drugs Revenue by Region ($ Million): 2026 - 2036
  • Figure 68: Asia Pacific Retinal Disorder Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 69: Europe Retinal Disorder Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 70: Middle East & Africa Retinal Disorder Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 71: Latin & Central America Retinal Disorder Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 72: North America Retinal Disorder Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 73: Global Retinal Disorder Drugs Market Revenue by Country ($ Million): 2026-2036
  • Figure 74: Australia Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 75: Brazil Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 76: Canada Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 77: China Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 78: Egypt Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 79: France Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 80: Germany Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 81: Greece Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 82: India Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 83: Israel Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 84: Italy Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 85: Japan Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 86: Mexico Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 87: Netherlands Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 88: Poland Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 89: Portugal Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 90: Russia Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 91: Saudi Arabia Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 92: South Africa Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 93: South Korea Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 94: Spain Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 95: Switzerland Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 96: Taiwan Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 97: Turkey Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 98: UK Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 99: USA Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 100: Rest of World Retinal Disorder Drugs Revenue ($ Million): 2026 - 2036
  • Figure 101: Global Retinal Disorder Drugs Revenue by Region ($ Million): 2026 vs 2036
  • Figure 102: Global Retinal Disorder Drugs Revenue by Region: Market Share 2026 vs 2036 (%)
  • Figure 103: Retinal Disorder Drugs CAGR % by Indication 2026 – 2036
  • Figure 104: Retinal Disorder Drugs: Incremental Revenue Growth by Indication ($ Million) 2026 vs 2036
  • Figure 105: Retinal Disorder Drugs Market Share % by Indication 2026 & 2036
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!